Interleukin-23 blockade: another breakthrough in the treatment of psoriasis
Abstract
Before risankizumab's introduction, there were ten biologic therapies approved for psoriasis, with two more in development. Do we really need all of these expensive therapies for this disease? A close look at the data shows that we do not have any treatments that reliably achieve complete clearing as evidenced by psoriasis area and severity index (PASI) 100, and only the newest treatments achieve PASI 90 in high proportions of patients....
Paper Details
Title
Interleukin-23 blockade: another breakthrough in the treatment of psoriasis
Published Date
Aug 1, 2019
Journal
Volume
394
Issue
10198
Pages
544 - 546
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History